Screener
Palvella Therapeutics PVLA Interest Income Expense Nonoperating Royalty Agreement
Interest Income Expense Nonoperating Royalty Agreement at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:InterestIncomeExpenseNonoperatingRoyaltyAgreement.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 14,855 | 7,871 |
| Operating loss | (14,855) | (7,871) |
| Other (expense) income: | ||
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
| Fair value adjustments on derivative liabilities – contingent value right liability | 202 | — |
| Interest income, net | 1,073 | 752 |
| Other income (expense), net | (32) | 224 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's interest income expense nonoperating royalty agreement?
- Palvella Therapeutics (PVLA) reported interest income expense nonoperating royalty agreement of -$2.04M in Q1 2026.
- How has Palvella Therapeutics's interest income expense nonoperating royalty agreement changed year-over-year?
- Palvella Therapeutics's interest income expense nonoperating royalty agreement decreased by 67.8% year-over-year, from -$1.22M to -$2.04M.
- What does interest income expense nonoperating royalty agreement mean?
- This represents non-operating financial obligations or income derived from royalty agreements linked to intellectual property or product commercialization rights. It captures the impact of contractual royalty payments or receipts that fall outside of core operational revenue and expense categories. Investors use this to assess the financial burden or benefit of external licensing arrangements.
Ask your AI about Palvella Therapeutics's interest income expense nonoperating royalty agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude